• Albina N Minlikeeva, Jo L Freudenheim, Wei-Hsuan Lo-Ciganic, Kevin H Eng, Grace Friel, Brenda Diergaarde, Francesmary Modugno, Rikki Cannioto, Emily Gower, J Brian Szender, Kassondra Grzankowski, Kunle Odunsi, Roberta B Ness, and Kirsten B Moysich.
• Department of Epidemiology and Environmental Health, University at Buffalo, Buffalo, New York.
• Cancer Epidemiol. Biomarkers Prev. 2015 Aug 1; 24 (8): 1291-4.

BackgroundUse of analgesics has been associated with lower risk of ovarian cancer, but, to date, very few studies have explored the association between analgesics and ovarian cancer survival.MethodsWe examined the relationship between self-reported prediagnostic use of aspirin, ibuprofen, and acetaminophen and overall survival (OS), progression-free survival (PFS), ascites at the time of primary treatment, and persistence of disease after primary treatment among 699 women diagnosed with epithelial ovarian carcinoma. The associations between use of these medications and OS and PFS were estimated using Cox proportional hazards models. We utilized unconditional logistic regression models to estimate associations between medication use and presence of ascites and persistence of disease.ResultsPrediagnostic intake of aspirin, both low-dose and regular-dose, ibuprofen, and acetaminophen was not associated with any of the outcomes of interest.ConclusionsOur results indicate a lack of association between prediagnostic intake of selected analgesics and OS, PFS, presence of ascites at the time of primary treatment, and persistence of disease after primary treatment.ImpactPrediagnostic intake of analgesics may not be associated with ovarian cancer outcomes.©2015 American Association for Cancer Research.

16 keywords...

hide…